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Abstract
Constitutive activation of FGFR1, through rearrangement with various dimerization domains, leads to atypical
myeloproliferative disorders where, although T cell lymphoma are common, the BCR-FGFR1 chimeric kinase results in
CML-like leukemia. As with the human disease, mouse bone marrow transduction/transplantation with BCR-FGFR1 leads to
CML-like myeloproliferation as well as B-cell leukemia/lymphoma. The murine disease described in this report is virtually
identical to the human disease in that both showed bi-lineage involvement of myeloid and B-cells, splenomegaly,
leukocytosis and bone marrow hypercellularity. A CD19
+ IgM
2 CD43
+ immunophenotype was seen both in primary tumors






2, suggesting a block in differentiation at the pro-B cell stage. The B220
2 phenotype was retained in
one of the cell lines while the other was B220
+. When the two cell lines were transplanted into syngeneic mice, all animals
developed the same B-lymphoblastic leukemia within 2-weeks. Thus, the murine model described here closely mimics the
human disease with bilineage myeloid and B-cell leukemia/lymphoma which provides a representative model to investigate
therapeutic intervention and a better understanding of the etiology of the disease.
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Introduction
The 8p11 myeloproliferative syndrome (EMS), also known as
stem cell leukemia lymphoma (SCLL) syndrome, is a distinct
clinico-pathological entity [1] defined by reciprocal chromosome
translocations that result in a chimeric protein with constitutive
activation of the kinase domain of the fibroblast growth factor
receptor-1 (FGFR1). As such, the WHO has now reclassified this
entity as a ‘‘myeloid and lymphoid neoplasm with FGFR1
abnormalities’’ [2,3]. The fusion partner protein provides the
oligomerization required for ligand-independent activated FGFR1
signaling, which is essential in pathogenesis [4]. To date, at least
11 FGFR1 fusion partners have been identified, most of which
induce a myeloproliferative neoplasm or disorder (MPN/MPD)
and lymphadenopathy, usually involving T-lymphoblastic lym-
phoma/leukemia predominantly of an immature T-cell type. The
t(8;22) variant translocation, results in a fusion between BCR
(breakpoint cluster region) and FGFR1 which is clinically distinct
from the myeloid/T-cell neoplasms of other variant FGFR1
fusions [5,6,7,8,9,10,11]. Leukemias in these patients are clinically
more similar to BCR-ABL1 induced CML, suggesting BCR may
play a role in this particular pathogenesis.
Currently, only eleven patients with the variant BCR-FGFR1
rearrangement have been described in detail. These patients were
usually diagnosed with an atypical CML (aCML) myeloid
neoplasm characterized by basophilia, splenomegaly, leukocytosis,
fibrosis and a hypercellular marrow, with an increase in immature
cells of the granulocyte series creating a left shift in granulopoiesis
[5,6,7,8,9,10,11]. In addition to aCML, 5 out of 11 BCR-FGFR1
patients also showed varying numbers of cells expressing B-cell
markers [6,7,9,11,12] and two of them presented with a pre-
dominantly acute precursor B-lymphoblastic leukemia (preB-ALL)
[6,12]. Only one patient developed both MPD and T-cell
lymphoblastic lymphoma [13]. Thus, the t(8;22) appears to be
able to induce a simultaneous myeloid and B lymphoid MPD.
In a murine model of BCR-FGFR1, Roumiantsev et al. [14]
demonstrated that the BCR-FGFR1 fusion kinase induced a CML-
like neoplasm devoid of T-cell lymphomas. The involvement of B-
cell proliferation in this model, however, was not reported, which
is inconsistent with the human disease. We recently described
a transduction-transplantation model of ZNF198-FGFR1-induced
SCLL, where the phenotype was almost identical to the human
disease [15]. We have now extended this approach to include
a model of BCR-FGFR1 induced leukemia were, in contrast to the
previous report, mice rapidly developed SCLL syndrome which
was similar to the human disease as evidenced by hepatospleno-
megaly, fibrosis and leukocytosis with progenitor, myeloid and B-
cell neoplasms in the bone marrow and spleen that were
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observations suggest that the BCR-FGFR1 fusion kinase induces
murine leukemia which is consistent with the human disease and,
in agreement with Murati and colleagues [9], suggests that BCR-
FGFR1 represents a distinct FGFR1 fusion-induced hematopoietic
neoplasm. During the course of these experiments we also
developed two cell lines from leukemic mice that are immuno-
phenotypically consistent with a pro-B cell progenitor.
Materials and Methods
Creation of the BCR-FGFR1 Mouse Model
The BCR-FGFR1 fusion cDNA construct, MSCV-GFP-BCR-
FGFR1, was a kind gift from Dr. Richard Van Etten [14]. The
original BCR-FGFR1 cDNA [7] was subcloned into the EcoRI-site
of a murine stem cell virus (MSCV) vector that contains an
internal ribosomal entry site (IRES) and the green fluorescent
protein (GFP) [14]. This insert was then subcloned into the EcoRI/
NotI site of the MIEG3 vector which provides enhanced GFP
(EGFP) expression (provided by Dr Wen Tao) [16]. Bone marrow
(BM) from donor mice was transduced with either MIEG3-BCR-
FGFR1 or MIEG3 in vitro as described previously [15]. Briefly,
BALB/cAnNTac (Taconic Farms), 6- to 8-week-old mice were
used throughout. For BM cell transduction, male donor mice were
first treated with 5-fluorouracil (150 mg/kg) intraperitoneal in-
jection, 2 days before the collection of BM cells. Recovered cells
were then incubated in IL2, IL3, and stem cell factor (final
concentration 100 ng/ml for each) for 24 hours before infection.
After prestimulation, 4 rounds of infection at 12-hour intervals
were performed with the retroviral supernatant (25% vol/vol) in
the presence of 10 g/ml polybrene, using the same media and
cytokines as described above. The infected BM cells (1.5610
6 cells
per mouse) were then injected into lethally or sublethally
irradiated (900 or 600 cGy respectively) recipient mice via tail
vein injection. All animal experiments were carried out under
protocol was approved by the Institutional Animal Care and Use
Committee of the Georgia Health Sciences University.
Histopathology
Peripheral blood smear and tissue fixation and staining were as
described previously [15].
Flow Cytometric Analysis
Antibody details are provided in Table S1 and staining methods
were as described previously [15].
Molecular Analyses
Total RNA was prepared using standard TRIzol (Invitrogen)
isolation and 5 ug of total RNA was retrotranscribed with
SuperScript first-strand synthesis III (Invitrogen) and 1 ml cDNA,
relative to 250 ng RNA, was amplified by PCR. Primers used to
identify the BCR-FGFR1 breakpoint were; Forward –
TGCCCTACATTGATGACTCG; Reverse – TTGGAGGCCA-
GATACTCCAT.
Cytogenetic and Comparative Genomic Hybridization
(CGH) Analyses
Chromosomes were analyzed using Spectral Karyotyping (SKY)
as described previously [17]. Genomic DNA was extracted from
BBC1 and BBC2 cells using standard methods and array CGH
was performed using Agilent’s SurePrint G3 Mouse CGH
Microarry 46180 K (G4839A, Agilent Technologies). Labeling
and hybridization of genomic DNA was performed according the
manufacturer’s instructions. DNA from a normal female Balb/c
mouse spleen was used as reference DNA during array-CGH.
After post-hybridization washes, the arrays were scanned and the
spot intensities were measured using ‘‘Feature Extraction Soft-
ware’’ (version 10.7, Agilent Technologies). The raw array data
was acquired using the feature Extraction Sofware and sub-
sequently analyzed by CGHWeb (http://compbio.med.harvard.
edu/CGHweb) using circular binary segmentation (CBS, al-
pha=0.05) algorithms.
Results
BCR-FGFR1 Induces Both a CML-like Myeloproliferative
Disease and B-cell Leukemia/lymphoma in a Mouse
Model
Donor bone marrow (BM) from three individual Balb/c founder
mice were transduced with the BCR-FGFR1-containing MIEG3
viral vector which was then transplanted into 5 lethally irradiated
(900 cGy) recipient mice. To investigate the effect of irradiation
dose on disease development, we also independently infected BM
cells from an additional 5 donor mice with BCR-FGFR1 retro-
supernatant. These infected BM cells were transplanted into 5
sublethally irradiated (600 cGy) recipients. One mouse in this
group died from irradiation shortly after transplantation and no
obvious disease development was noted. Approximately 2-weeks
following the primary transplantation, analysis of peripheral blood
samples from these animals showed that the WBC count in the
peripheral blood began to reconstitute and increase, suggesting
successful engraftment. By 3 to 4 weeks post-transplantation the
WBC count was remarkably increased in all lethally irradiated
recipients (Figure 1A). Abnormal leukocytes with ring-shaped
nuclei and blast cells were frequently seen in this cohort of mice
(Figure 1A), indicative of the development of leukemia. The
increase of WBC count or abnormal leukocytes were only seen
after ,2 months post-transplantation in sublethally irradiated
recipients. The median survival time in the lethally irradiated
cohort (n=5) was 3066.5 days post-transplantation, while the
600 cGy cohort (n=4) it was 83652.5 days (Figure 1B). Except
for this longer latency period, we did not observe any differences
between lethally and sublethally irradiated recipients based on
their immunophenotypes (see below). Five mice transduced and
transplanted with the empty MIEG3 vector did not develop
disease over a one year observational period.
Pathological analysis showed that all of the diseased mice
showed significantly enlarged spleens (p=0.006) and livers
(p=0.0004) compared with normal mice (Figure 1C and D).
Enlarged Peyer’s patches were observed in 8 out of 9 recipients
(Figure 1D) and enlarged mesenteric lymph nodes were seen in
about 40% mice (Figure 1D). Peripheral lymph nodes were
infrequently enlarged. Molecular imaging of the liver, spleen and
femur and a fragment of intestine showed GFP positive cells
distributed throughout these organs, indicating that they were
derived from transformed cells from the donor mice (Figure 1D,
bottom). Furthermore, histopathological analyses of the primary
transplanted mice showed that the disease was accompanied by
hyper-cellularity in the bone morrow from the sternum, and
leukocyte infiltration into multiple organs, such as the lung
(Figure 1E), liver and heart (data not shown).
B-cell Leukemia in BCR-FGFR1 Disease Suggests a Block
at the Pro-B Stage
Expression of EGFP in the BCR-FGFR1 transformed leukemic
cells conveniently permitted flow cytometric analysis of cells
carrying the fusion kinase. Premature death of one founder mouse
BCR-FGFR1 Induced ProB-Cell Lymphoma
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were used in subsequent analyses. Flow cytometric analysis using
lineage-specific markers was performed in all the available primary
recipients. An analysis of GFP
+ splenocytes using B cell markers






+ myeloid cells in the spleen showed co-
expression of Mac-1 and Gr-1 (Figure 2A) and, in all but one
mouse, were found at lower frequencies than the GFP
+ B cells. As
an exception, the majority of GFP
+ cells in mouse #1 and #2
were Mac-1
+Gr-1
+ (Figure S1A) suggesting a predominantly
myeloid disease. Since early B-cell development is mainly located
in the bone marrow, we also analysed the bone marrow compared
with the peripheral blood cells from all the disease mice, which
showed a similar phenotype (Figure 2B and C). During this
analysis, we noticed that peripheral blood from several primary
recipients had lost GFP expression, even though bone marrow
cells in these animals contained GFP
+ cells, and RT-PCR analysis
demonstrated that these GFP
2 cells carried the BCR-FGFR1
fusion gene (Figure 2C). In all the primary recipients, very few




the possibility of T-cell disease. Most of the primary transplanted
mice showed enlarged lymph nodes and/or tumors in their





(Figure 2D) which is consistent with a pro-B cell phenotype
(Figure 2D). During these analyses we noticed that the GFP
+ cells
only accounted for ,20% of whole cell population, suggesting that
most tumor cells had lost GFP expression. Consistent with this
suggestion, the majority of GFP negative cells shared the same











+ (Figure S1). Furthermore, the BBC1 cell line
derived from one primary recipient is GFP negative and expresses
the BCR-FGFR1 fusion protein (Figure 2A and 4A). Overall,
therefore, BCR-FGFR1 induced both myeloid leukemia and B-cell
leukemia/lymphoma blocked at the pro-B stage in most mice and
there was no evidence of T-cell disease.
Murine Leukemia/lymphoma Induced by BCR-FGFR1 is
Transplantable
To determine transplantability of these lymphomas, BM cells
from the 5 lethally irradiated mice were each transplanted into 3–5
secondary recipients that had been sublethally irradiated (600 Gy).
Depending on the number of cells obtained from the primary
transplanted mice, 0.6–1.5610
6 cells were transplanted and
leukemias developed within 2–10 weeks suggesting fully trans-
formed leukemic stem cells were present in the BM. The latency
period in the secondary transplanted mice was similar to that seen
in the primary recipients and the median survival time was , 30
days (Figure 3A). The immunophenotype of the secondary
transplanted mice was also similar to that in the primary mice
(Figure 3B). Because all secondary transplanted mice simulta-
neously developed transplantable myeloid and B-lineage disease
suggests that the disease initiates from progenitor cells or stem
cells.
BCR-FGFR1 Derived Cell Lines with Pro-B Progenitor
Immunophenotypes
Cells from the both bone marrow and spleen of leukemic mice
were routinely cultured in standard growth medium supplemented
with 5% FBS. In two cases (#5 and #7), progressively growing cell
lines were established from bone marrow samples. These cell lines
are referred to as BBC (BCR-FGFR1 Bone marrow Cells) 1 and 2
and have been grown in suspension for over 50 passages in vitro
under normal growth conditions without addition of growth
factors. RT-PCR analysis across the breakpoint demonstrated the
presence of the BCR-FGFR1 fusion transcript in both cases (not
shown) and western blot analysis also confirmed that they both
express the BCR-FGFR1 fusion protein (Figure 4A). RT-PCR
analysis showed BBC1 cells express TdT, RAG1, EBF-1 and Pax-
5 suggesting an immature B cell lineage (data not shown). Analysis
of the immunoglobulin rearrangements in these cells demonstrated
a germline configuration in the BBC1 cells, whereas BBC2 cells
showed oligoclonal rearrangements (Figure 4B). FACS analysis of










(Figure 4C). A sub-population of CD19
+B220
2 cells was also
seen in the primary donor that gave rise to these cells (Figure 2B),
which was also observed in 2 other founder mice (Figure S1). The







+ but in this case was
B220
+ supporting a pro-B cell origin. These cells also expressed
CD4 (Figure 4C), demonstrating biphenotypic characteristics seen
in cells from SCLL patients.
BBC Cells Rapidly Induce Disease in Mice
When BBC1 or BBC2 cells were transplanted, individually
into normal BALB/c mice, aggressive leukemia/lymphoma and
splenomegaly developed in all cases after only 14 days (Figure
S2). In addition, leukocytosis (Figure S2B) and infiltration into
various organs was observed (Figure S2C). Histopathologically,
spleens show intense extramedullary leukocyte proliferation,
including maturing but mostly numerous precursor and blast
forms, together with dysplastic megakaryocytes (Figure S2D).
Cytogenetic Analysis of BBC Cell Lines
Analysis of the chromosomes from the BBC1 cell line at an
early stage (passage 5–10) using Spectral Karyotyping (SKY),
demonstrated highly unstable karyotypes with multiple trisomies
and a large variation in the chromosome composition between
individual cells. Examples in Figure 5 show different clones
within the parent cell population. The only chromosome
translocation identified was a t(4;14) which was only seen in 3/
51 metaphases analyzed and to our knowledge has not been
reported previously. Comparative genome hybridization (CGH)
Figure 1. A mouse model of BCR-FGFR1 induced leukemia is consistent with the human disease. (A) May-Gru ¨nwald-Giemsa staining of
peripheral blood showing an increase of white blood cells and the presence of blasts with a more mature myeloid chronic-like phenotype from
mouse #1 (above) and a more blast-like phenotype from mouse #5 (below) compared with BM from mice reconstituted with the MIEG3 vector. (B)
Survival curves for mice receiving either 900 centiGray or 600 centiGray shows a longer latency period for the lower dose and longer survival
compared with MIEG3 controls. (C) The average spleen and liver weight of BCR-FGFR1 recipients (n=8) were significantly increased compared to
MIEG3 mice (n=5), (** p,0.01). (D) BCR-FGFR1 induced leukemia characterized by (i) hepatosplenomegaly and visible splenic fibrosis, (ii) pulmonary
infiltration, enlarged Peyer’s patches (iii, arrows) and a mesenteric lymph node (iv, arrow). Molecular imaging of GFP defined tumor cell populations in
the liver (v), Peyer’s patches (vi) and spleen (vii). (D) H&E stained BCR-FGFR1 recipient tissues shows hypercellular bone marrow with a predominant
increase in myeloid and megakaryocytic lineages, spleen with extramedullary myeloid proliferation including dysplastic megakaryocytes (middle) and
infiltrating myeloid cells in the lung which is consistent with D (ii). Tissues from control animals are shown below for comparison.
doi:10.1371/journal.pone.0038265.g001
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evolution of the chromosome content (Figure 5) with many whole
chromosome losses and gains. CGH analysis of BBC2 similarly
showed extensive chromosome aneuploidy where some of the
changes were in common with BBC1 cells, although others were
specific to BBC2. Common changes in the two cells lines were;
21, 22, +3, +5, +6, +8, 29, +10, +15 and 216. The high level
of aneuploidy in these B-lymphoma cell lines is in contrast with
those seen in the T-lymphoma cell line carrying the ZNF198-
FGFR1 chimeric kinase [15] where only minimal aneuploidy was
noted with a deletion of the TCRA locus on chromosome 14.
This deletion was not seen in the BBC1/2 cell lines.
Figure 2. BCR-FGFR1 simultaneously induces B-cell leukemia/lymphoma and myeloid proliferative disorder. Representative flow
cytometric analysis of bone marrow (A), spleen (B) and peripheral blood (C) cells from primary transplanted mouse #5 with BCR-FGFR1-induced
disease shows that the majority of B-cells are arrested at pro-B stage with a CD19
+IgM
2 immunophenotype in both GFP positive and negative cells.
The presence of GFP
+Mac-1
+Gr-1
+ populations, as well as high levels of GFP
2Mac-1
+Gr-1
+ cells, was also seen. Very few T-lineage (CD4
+ and/or CD8
+)
cells were present in the leukemic spleen. GFP expression was lost in the peripheral blood from the majority of primary recipients, where the BCR-
FGFR1 fusion transcript can be detected by RT-PCR (C, below). D) Most of the primary transplanted mice showed enlarged lymph nodes and/or
tumors in their abdomens. Representative flow cytometric analysis of the tumor cells shows the predominantly pro-B lymphoma immunophenotype,
CD19
+IgM
2. E) Schematic diagram showing the progression of B-cell development from hematopoietic stem cells (HSC) and common lymphoid
progenitors (CLP) into mature B cells and plasma cells. The immunophenotype of the B-lineage cells carrying the BCR-FGFR1 fusion kinase suggests
an arrest at the pro-B stage of development as indicated.
doi:10.1371/journal.pone.0038265.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38265Figure 3. B-cell leukemia/lymphoma induced by BCR-FGFR1 is transplantable. A) Kaplan-Meier survival analysis of the second generation
of BCR-FGFR1 mice, which were transplanted with BM cells (0.6–1.5610
6 cell per mouse) from lethally irradiated primary recipients. B) Representative
flow analysis shows that lymphoma/tumor cells from a second serial transplanted mouse are differentially blocked at the pro-B stage.
doi:10.1371/journal.pone.0038265.g003
Figure 4. BCR-FGFR1 derived cell lines are consistent with an pro-B cell phenotype. (A) Western blot analysis shows the presence of the
120 kD BCR-FGFR1 fusion protein in BBC1 and BBC2 cells compared with normal thymocytes. (B) Genomic PCR analysis of IgH rearrangement
showing the germline configuration in the tail and polyclonal rearrangements in the spleen from normal mice. (C) Flow analysis of BBC1 and BBC2 cell
lines demonstrates an immature B-cell immunophenotype.
doi:10.1371/journal.pone.0038265.g004
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The EMS/SCLL-related leukemia/lymphoma syndromes rep-
resent a subgroup of cancers for which the prognosis is dismal,
even despite chemotherapy and BMT [4]. Despite the clear
involvement of the FGFR1 fusion kinases, still relatively little is
known about the etiology of these diseases and the distinct
phenotypes seen in patients with the rarer FGFR1 rearrangements
provides an opportunity to dissect their subtle differences. Since
the biphenotypic nature of the disease implies a multipotent cell
origin, SCLL provides an opportunity to gain a better un-
derstanding of the fundamental genetic changes that occur during
development and progression of this disease. We have now shown
the involvement of a pro-B cell in a mouse model of BCR-FGFR1
SCLL, which may guide future studies in the analysis of the
human disease. As a result, more customized approaches or
possible alternative therapies may be suggested based on a more
detailed analysis of these tumor cells.
To date, BCR-FGFR1 SCLL patients show different manifesta-
tions of the disease with some showing B-cell lymphomas as well as
myeloid disease. Although it is a common finding that leukemias
demonstrate lineage infidelity for their immunophenotypes, the
disease in the mice described in this report clearly show
characteristics consistent with the human disease. In both species,
bi-lineage involvement of myeloid and B-cells, splenomegaly,
leukocytosis and bone marrow hypercellularity are common. In
addition, during our analysis, all founder mice had a chronic-like,
or a B-cell blast-like phase, although none progressed to AML. In
a previous report [14] it was suggested that BCR-FGFR1
produced myeloid disease, with no evidence of B-cell lymphoma.
It is difficult to determine why the disease is apparently different in
what was essentially the same bone marrow transduction and
transplantation experimental approach. Although we used an
Figure 5. Karyotypic analysis of B-lymphoma cell lines. CGH analysis (A) of BBC1 (above) and BBC2 (below) show distinct chromosome
changes in the two cell lines. SKY analysis of BBC1 cells (B) demonstrates extensive aneuploidy and, in one metaphase, a t(4;14) non-reciprocal
chromosome translocation.
doi:10.1371/journal.pone.0038265.g005
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placement of traditional GFP with an enhanced GFP reporter in
this vector. Both constructs are based on the murine stem cell
virus. It has been reported that transformation of bone marrow
cells with the BCR-ABL1 fusion kinase induces different lineage
diseases depending on whether the donor mice were treated with
5-FU before collection of the BM cells, as well as whether
cytokines were used during infection of the BM cells [18]. In our
procedure, the donor mice were treated with 5-FU and the BM
cells and cultured with the same cytokines as in the previous report
[14] We used 150 mg/kg 5-FU to treat the donor mice compared
with 200 mg/kg [14]. We do not believe that this minor difference
can drive the developed of pro-B cell leukemia and lymphoma.
Moreover, we have shown that ZNF198-FGFR1-transduced bone
marrow cells developed MPD together exclusively with T-cell
lymphoma [15]. Using exactly the same approach, we now show
that BCR-FGFR1 transduced bone marrow developed CML-like
disease together with only B-cell leukemia/lymphoma in two
independent series of experiments. These observations suggest that
it is perhaps the specific chimeric FGFR1 fusion kinase that drives
the disease development into different lineages rather than the
experimental approach or individual mouse strain. In the previous
study [14], however, it appears that the absence of B-cell
lymphomas was based on an analysis using only the B220 marker,
which was negative on the GFP
+ cells. Ordinarily this would
exclude a B-cell lineage, although in our study we also analysed
other early B-cell markers where, in mouse #5 for example,
a predominantly B220
2 B-cell lymphoma was seen. In most other
mice there were subpopulations of B220
2 as well as B220
+ B-cells.
Two of the mice in this study (#1 and #2), however, also showed
a predominantly (B220
2) myeloid disease (Figure S1), although
there were sub-populations of CD43
+ and CD19
+ cells. Most of
the other 7 mice showed B220
+ and B220
2 populations that were
CD19
+ and CD43
+. Thus, since CD19 and CD43 markers were
not assayed in the previous study [14], it is possible that the
lymphomas in this study were, in fact, pro-B cells similar to the
BBC1 cells.
The murine stem cell virus-based vector with bi-cistronic
expression of GFP has become more frequently used to generate
murine bone marrow transduced and transplantation models, as
well as human CD34+ xenotransplantation mouse models [19,20].
We noticed, however, that not all transformed cells simultaneously
expressed chimeric FGFR1 and GFP in this study as well as in
either the ZMYM2-FGFR1 model [21] or a CEP110-FGFR1
mouse model (Ren et al, manuscript under preparation). We now
show that this is probably due to inactivation of GFP expression in
the transformed cells during their evolution. Careful analysis of the
GFP negative cells demonstrated that they showed the same
immunophenotype as the GFP+ cells in the same animal and that
they expressed the BCR-FGFR1 chimeric protein.
In summary we have established a representative murine model
for BCR-FGFR1 SCLL that has extensive similarities to the
human disease and so provides a model that can be used to
investigate novel therapeutics for an aggressive disease that is
currently refractory to therapy. Although rare, the mechanism by
which BCR-FGFR1 SCLL progresses, also represents a model for
cancer with clonal evolution that is likely shared by other MPDs
and other common cancers. Furthermore, in this model, the
molecular pathways that contribute to the transformation to B-
ALL, rather than AML, provides an opportunity to investigate the
etiology of disease progression in SCLL patients.
Supporting Information
Figure S1 BCR-FGFR1 induced mouse developed mye-
loid or pro-B leukemia. Flow cytometric analysis of bone
marrow (BM) and spleen (SP) cells from mouse #1 (A and B
respectively) and mouse #2 (C and D respectively) from the 5
primary lethally irradiated recipients shows a high percentage of
Gr1
+Mac1
+ cells or/and pro-B leukemia, but fewer cells express
CD4 or CD8. These phenotypic analyses are compared to BM (E)
and spleen (F) samples from mice which were reconstituted with
cells carrying the empty MIEG3 vector.
(TIF)
Figure S2 BBC1 recipient mice develop leukemia/
lymphoma. (A) Spleen weight of BBC1 recipients were increased
compared to normal mice of the same age, (** p=0.002). (B) May-
Gru ¨nwald-Giemsa staining of peripheral blood showing dysplastic
leukocytosis and the presence of blasts (C) BBC1 transplanted mice
with hind leg paralysis, inflamed inguinal lymph nodes, formation
of large masses on the lower spinal region or in the gut,
accumulation of urine, cerebral hemorrhaging or intracranial
bleeding and peritoneal membrane thickening. (D) H&E stained
BBC spleen shows involvement of myeloproliferative process with
acute leukemic transformation.
(DOCX)
Table S1 Antibodies used in flow analysis.
(DOCX)
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